Compare ACADIA Pharmaceuticals Inc. (ACAD) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs NextEra Energy, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while NextEra Energy, Inc. trades at $87.57 (market cap $184.51B). The key difference: NextEra Energy, Inc. is far larger — about 41.1× ACADIA Pharmaceuticals Inc.'s market cap, and NextEra Energy, Inc. pays a 2.82% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NEE | |
|---|---|---|
Market Cap | $4.49B | $184.51B |
Sector | Health | Utilities |
52-Week High | $28.06 | $97.88 |
52-Week Low | $20.06 | $69.77 |
Enterprise Value | $3.69B | $286.92B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
NextEra Energy (NEE) trades at $88.47, up 0.15% today, with a neutral technical outlook and strong analyst support. The stock shows solid fundamentals with a P/E of 22.19, net income margin of 29.37%, and recent earnings beats in Q1 2026. Revenue grew to $27.41B in 2025, though net income dipped slightly to $6.84B. A recent $0.62 dividend underscores shareholder returns, while the Dominion Energy merger positions NEE for AI-driven power demand growth.
Outlook remains positive with a consensus price target of $104.29 (18% upside), driven by clean energy demand and partnerships. Risks include rising debt-to-asset ratios (47.6% in 2025) and regulatory pressures. Institutional sentiment is bullish with 66.7% buy ratings, but investors should monitor execution on capital expenditures and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
